🇺🇸 FDA
Patent

US 12065458

Trialkyne linking agents and methods of use

granted A61KA61K47/545

Quick answer

US patent 12065458 (Trialkyne linking agents and methods of use) held by Arrowhead Pharmaceuticals, Inc. expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K47/545